This Is Why Investors Will Need to Learn a New Acronym: CRISPR
In this Market Foolery segment, host Chris Hill and Motley Fool Rule Breakers' Aaron Bush talk about where genetic engineering is heading -- which is out of the lab and toward really curing diseases. Yes, it's early days. But the potential for CRISPR could be enormous. But there are some interesting speedbumps involved for biotech investors.
A full transcript follows the video.
Source: Fool.com
CRISPR Therapeutics AG Stock
€41.40
-
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the CRISPR Therapeutics AG stock is not clear.
Based on the current price of 41.4 € the target price of 200 € shows a potential of 383.09% for CRISPR Therapeutics AG which would more than double the current price.